All Access

Health Tech Deals

Standard

Health Tech Deals Thought Bubble

Thought Bubble

Health Tech Deals Alerts

Alert

mustard

BFD Expert Voices - Health Tech Deals

BFD Expert Voices

Sano Genetics, a software platform to facilitate precision medicine-powered clinical trials, raised $11.4 million in funding, CEO Patrick Short tells Axios exclusively. 

Why it matters: AI can make traditional clinical trials — which are very expensive and take years to complete — more efficient and effective. 

Details: The round was led by Plural with participation from existing investors including MMC Ventures, Episode 1 and Seedcamp.

This most recent round of funding brings the total raised by the company to $22 million.

How it works: The Cambridge, England-based company is an end-to-end precision medicine-based clinical trial software platform.

Sano connects patients in the United Kingdom, U.S., Australia and Canada with pharmaceutical companies and biotech companies conducting clinical trials, making it easier for patients to access precision medical treatment.

Once patients are recruited, customers use Sano's platform to manage  aspects of the trial including participant communication, facilitating genetic and other biomarker testing, returning results and supporting patients with genetic counseling.

The big picture: Clinical trials that use genetic data have a 26% success rate compared to 10% for standard clinical trials.

What's next: Fresh funds will be used to meet the growing demand for its products, leverage AI further and expand its reach to more countries.

"We will probably raise again by the end of this year or early next year if we continue to grow at this pace," Short says.

While the company is focused on genetics, it will eventually branch out into other areas such as metabolomics and proteomics using data to prevent, treat and diagnose diseases.

Of note: While there is no label on this round, Short confirmed the fresh funding was a up-round for the company. 

"We are profitable on a unit basis and we could be profitable overall if we allocated money differently, but we will be in growth mode for a long time," he says.

What they're saying: "Five years ago less than 5% of the market" comprised precision medicine," says Carina Namih, partner at Plural.

Carina believes that by the end of the decade, more than 80% of trials will use genetic testing or other biomarkers. 

"Sano is the only end to end software platform that enables pharmaceuticals to run this trial with a precision element," she says. 

1 fun thing: The word Sano in Latin means healthy. 

are very expensive and take years to complete

Exclusive: Sano Genetics nabs $11.4M for precision medicine trials

The company's software could improve clinical trial efficiency.

Illustration of an AI brain surrounded by shapes, health crosses, and money elements. 

Health tech deals

Sano Genetics, a software platform to facilitate precision medicine-powered clinical trials, raised $11.4 million in funding, CEO Patrick Short tells Axios exclusively. Why it matters: AI can make traditional clinical trials — which <a class="gtmContentClick" data-vars-link-text="are very expensive and take years to complete" data-vars-click-url="https://manhattan.institute/article/slow-costly-clinical-trials-drag-down-biomedical-breakthroughs" data-vars-content-id="6fd5a3ba-5607-42d2-9721-2a690c3e2f50" data-vars-headline="Exclusive: Sano Genetics nabs $11.4M for precision medicine trials" data-vars-event-category="story" data-vars-sub-category="story" data-vars-item="in_content_link" href="https://manhattan.institute/article/slow-costly-clinical-trials-drag-down-biomedical-breakthroughs" target="_blank">are very expensive and take years to complete</a> — more efficient and effective.

topics

politics-policy

epstein-files

donald-trump

2026-midterm-elections

immigration

behind-the-curtain

race-and-equity

technology

privacy-tech-regulation

automation-and-ai

tiktok-news

big-tech

social-media

cybersecurity

economy

social-security

inflation

tariffs

federal-reserve

transportation

business

c-suite

retail-news

media

elon-musk

dealmaking

health

rfk-jr

drug-prices

axios-explains-abortion

public-health

world

israel

axios-explains-ukraine

iran

russia

china

energy-climate

nuclear-energy

climate-energy-policy

climate-change

extreme-weather

alternative-energy

electric-vehicles

science

emerging-tech

biomedicine

newsletters

charlotte

salt-lake-city

denver

fort-lauderdale

cincinnati

scottsdale

boulder

kansas-city

austin

chicago

dallas

detroit

atlanta

indianapolis

nashville

nw-arkansas

columbus

hollywood

washington-dc

north-of-cincy

mesa

richmond

san-francisco

boston

des-moines

houston

phoenix

miami

philadelphia

seattle

new-orleans

colorado-springs

huntsville

raleigh

san-antonio

twin-cities

pittsburgh

san-diego

tampa-bay

portland

cleveland

arapahoe

douglas

axios-local

axios-pro

axios-live

the-axios-show

Exclusive: Sano Genetics nabs $11.4M for precision medicine trials

What to read next